Ultragenyx Pharmaceutical Inc. $RARE Stock Holdings Increased by Candriam S.C.A.

Candriam S.C.A. lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 37.1% in the 1st quarter, HoldingsChannel reports. The firm owned 1,096,182 shares of the biopharmaceutical company’s stock after purchasing an additional 296,798 shares during the quarter. Candriam S.C.A.’s holdings in Ultragenyx Pharmaceutical were worth $22,965,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of RARE. Leonteq Securities AG lifted its holdings in Ultragenyx Pharmaceutical by 288.5% in the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,333 shares during the period. Danske Bank A S bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $39,000. Aster Capital Management DIFC Ltd bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $56,000. Smartleaf Asset Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 43.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 751 shares during the period. Finally, Empowered Funds LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $66,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $24.62, for a total transaction of $46,753.38. Following the transaction, the executive vice president directly owned 94,462 shares in the company, valued at approximately $2,325,654.44. The trade was a 1.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $25.05, for a total transaction of $50,100.00. Following the sale, the director directly owned 21,095 shares in the company, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 19,319 shares of company stock valued at $476,837 over the last ninety days. Corporate insiders own 5.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on RARE shares. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. Wells Fargo & Company upped their price objective on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Wedbush lowered their target price on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Royal Bank Of Canada boosted their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Finally, Truist Financial raised shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $58.41.

Ultragenyx Pharmaceutical Trading Down 2.3%

Shares of NASDAQ RARE traded down $0.79 during mid-day trading on Friday, reaching $33.82. The company had a trading volume of 1,578,135 shares, compared to its average volume of 3,166,224. The company has a 50-day moving average price of $26.71 and a two-hundred day moving average price of $24.57. The stock has a market cap of $3.33 billion, a PE ratio of -5.54 and a beta of 0.31. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.29 and a 1-year high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The company had revenue of $136.00 million for the quarter, compared to analysts’ expectations of $158.19 million. During the same period in the prior year, the company earned ($1.57) earnings per share. The company’s revenue for the quarter was down 2.2% on a year-over-year basis. On average, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.53 EPS for the current year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.